Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 9/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.39 |
| ▸ | INSR | P06213 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26397198 | 0.87 | EGFR (0.47) | PLK1EGFRALKIGF1R | |
| SCHEMBL26397089 | 0.82 | EGFR (0.47) | PLK1EGFRALKIGF1RJAK2 | |
| SCHEMBL26397273 | 0.82 | EGFR (0.57) | PLK1EGFRALKINSRIGF1R | |
| SCHEMBL26401884 | 0.81 | EGFR (0.48) | PLK1EGFRALKIGF1RBRD4 | |
| SCHEMBL26402950 | 0.79 | ALK (0.63) | PLK1EGFRALKPDGFRBPDGFRA | |
| SCHEMBL26385374 | 0.75 | EGFR (0.60) | PLK1EGFR | |
| SCHEMBL26385363 | 0.75 | EGFR (0.68) | PLK1EGFR | |
| SCHEMBL26397144 | 0.74 | JAK3 (0.43) | PLK1EGFRALKIGF1RJAK3 | |
| SCHEMBL26385402 | 0.74 | EGFR (0.62) | PLK1EGFRALK | |
| SCHEMBL26395755 | 0.74 | ALK (0.57) | PLK1EGFRALKINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | PLK1 267/4885EGFR 1/4885ALK 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.